MYMiao Yin

Miao Yin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Miao Yin has a total of 80 co-authors. Here are the top co-authors by number of shared publications:

  • Qun-Ying Lei

    Fudan University Shanghai Cancer Center & School of Basic Medical Sciences and Institutes of Biomedical Sciences; Cancer Institutes; Key Laboratory of Breast Cancer in Shanghai; Shanghai Key Laboratory of Radiation Oncology; Shanghai Key Laboratory of Medical Epigenetics, Shanghai Medical College, Fudan University, Shanghai, China

    19 shared publications
  • Chao Wang

    5 shared publications
  • Jin-Tao Li

    Fudan University Shanghai Cancer Center & Institutes of Biomedical Sciences; Cancer Institutes; Key Laboratory of Breast Cancer in Shanghai; Shanghai Key Laboratory of Radiation Oncology, the Shanghai Key Laboratory of Medical Epigenetics, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China

    5 shared publications
  • Fan Zhang

    Fudan University Shanghai Cancer Center & Institutes of Biomedical Sciences; Cancer Institutes; Key Laboratory of Breast Cancer in Shanghai; Shanghai Key Laboratory of Radiation Oncology; Shanghai Key Laboratory of Medical Epigenetics; National Key Laboratory of Brain Function and Diseases; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

    4 shared publications
  • Lei Zhang

    Institutes of Biomedical Sciences, Fudan University, Shanghai, China

    4 shared publications
  • Wen-Ying Zhu

    Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences and School of Basic Medical Sciences; Cancer Institutes; Key Laboratory of Breast Cancer in Shanghai; Shanghai Key Laboratory of Radiation Oncology; Shanghai Key Laboratory of Medical Epigenetics; National Key Laboratory of Brain Function and Diseases; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

    4 shared publications

Latest Publications

  • Open Access

    Tumor-intrinsic NLRX1-mediated mitophagy drives immune evasion through extracellular lipid remodeling

    by Chao Wang, Yuan Shen, Luhang Jiang, Miao Yin, Yifan Zhang, Qun-Ying Lei

  • Open Access

    Malic enzyme 1 senses L-lactate to determine tumor heterogeneity

    by Si-Yi Cao, Kewen Hu, Shijing Huang, Xiao-Lin Guan, Jian Wang, Yuan Shen, Hui Ming, Aihong Gu, Chao Wang, Xiao Shen, et al.

    L-lactate is generally elevated in tumors and acts as a signaling molecule that promotes tumor progression. Here, we reveal that malic enzyme 1 (ME1) functions as a previously unrecognized sensor of L-lactate through direct binding at arginine 155 (R155), thereby potentiating malignancy. Mechanistically, L-lactate binding promotes the nuclear translocation of ME1, a process involving reduced acetylation at lysine 362 (K362) and facilitated by nuclear import of karyopherin-α 4 (KPNA4). Nuclear accumulation of ME1 enhances metastatic potential, which is correlated with increased interaction with hepatoma-derived growth factor (HDGF) and acquisition of an epithelial‒mesenchymal transition (EMT)-related phenotype. Under nutrient-deficient conditions, L-lactate promotes the assembly of a ME1-lactate dehydrogenase B (LDHB) complex, which enhances oxidative phosphorylation (OXPHOS) and increases ATP production, suggesting a metabolic adaptive mechanism that supports tumor cell survival. Notably, the ME1 R155A mutation, which disrupts L-lactate binding, abolishes the protumorigenic effect of the L-lactate-ME1 axis on tumor progression in vivo. In conclusion, our findings identify ME1 as a direct sensor of L-lactate and support a model in which lactate-mediated signaling and metabolic adaptation converge on ME1 to regulate tumor cell plasticity in a context-dependent manner under heterogeneous metabolic conditions. These insights advance our understanding of the spatiotemporal control of metabolic adaptation in cancer and reveal a potential therapeutic target.


  • Tumor-derived branched-chain α-keto acids activate Notch signaling in tumor-associated macrophages to limit immunity

    by Qi-Xiang Ma, Ru Zhao, Jiang-Xue Han, Wen-Ying Zhu, Mi-Die Xu, Xiao-Yan Zhang, Guo-Quan Yan, Wen-Yu Wen, Guang-Chun Han, Min Luo, et al.

    Tumor cells are highly dependent on branched-chain amino acids, which can activate mechanistic target of rapamycin complex 1, but the downstream catabolite branched-chain α-keto acids (BCKAs) are not well studied in this context. Here, using clinical samples and genetically engineered mouse tumor models, we showed that tumor-derived BCKAs are secreted actively into the tumor microenvironment (TME) where they reprogram tumor-associated macrophages (TAMs) to promote tumor progression. Through genome-wide CRISPR screening, we identified Notch2 as a direct molecular target of BCKAs. BCKAs activate Notch signaling by binding to and stabilizing cleaved Notch2, functionally reprogramming TAMs and fostering an immunosuppressive TME. Mutation of the BCKA-binding site in Notch2 abolishes this effect in vivo. Together, these findings identify BCKAs as signaling metabolites that mediate tumor immunosuppression through direct sensing by Notch2.


  • Targeting methionine-induced pyroptosis enhances anti-tumor immunity

    by Mingzhu Lei, Wenying Zhu, Chao Wang, Fan Zhang, Miaolin Li, Yi Zhang, Jia Qu, Zhiguo Luo, Jintao Li, Zeng-Xia Li, et al.

    Pyroptosis is an inflammatory form of programmed cell death that plays a critical role in tumor immunity. However, the metabolic signals involved in this process remain undefined. In the present study, we uncover that methionine metabolism plays an important role in the pyroptosis of bone marrow-derived macrophages (BMDMs). The depletion of methionine adenosyltransferase 2A (Mat2a) in macrophages leads to cell death by activating GSDME, resulting in suppression of tumor growth in vivo. Furthermore, pharmacological inhibition of MAT2A induces macrophage pyroptosis by activating Gasdermin E (GSDME) but not Gasdermin D (GSDMD). Moreover, we identify a natural compound 1,2,3,4,6-O-pentagalloylglucose (PGG), not only inhibiting the enzymatic activity of MAT2A but also promoting its proteasome degradation through E3 ligase SMURF1-mediated polyubiquitylation. Consequently, PGG can induce pyroptosis by cleaving GSDME in various tumor cells and suppress tumor cell growth through enhancing anti-tumor immune response. Collectively, our findings reveal that MAT2A is an essential metabolic regulator of pyroptosis, and PGG could potentially boost anti-tumor immunity by targeting MAT2A.


  • Spatio-temporal metabolic alterations in cachexia

    by Hui Ming, Miao Yin, Qun-Ying Lei

  • Open Access

    Cytosolic acetyl-coenzyme A is a signalling metabolite to control mitophagy

    by Yifan Zhang, Xiao Shen, Yuan Shen, Chao Wang, Chengping Yu, Jiangxue Han, Siyi Cao, Lin Qian, Miaolian Ma, Shijing Huang, et al.

    Acetyl-coenzyme A (AcCoA) sits at the nexus of nutrient metabolism and shuttles between the canonical and non-canonical tricarboxylic acid cycle1,2, which is dynamically regulated by nutritional status, such as fasting3. Here we find that mitophagy is triggered after a reduction in cytosolic AcCoA levels through short-term fasting and through inhibition of ATP-citrate lyase (encoded by ACLY), mitochondrial citrate/malate antiporter (encoded by SLC25A1) or acyl-CoA synthetase short chain family member 2 (encoded by ACSS2), and the mitophagy can be counteracted by acetate supplementation. Notably, NOD-like receptor (NLR) family member X1 (NLRX1) mediates this effect. Disrupting NLRX1 abolishes cytosolic AcCoA reduction-induced mitophagy both in vitro and in vivo. Mechanically, the mitochondria outer-membrane-localized NLRX1 directly binds to cytosolic AcCoA within a conserved pocket on its leucine-rich repeat (LRR) domain. Moreover, AcCoA binds to the LRR domain and enhances its interaction with the nucleotide-binding and oligomerization (NACHT) domain, which helps to maintain NLRX1 in an autoinhibited state and prevents the association between NLRX1 and light chain 3 (LC3). Furthermore, we find that the AcCoA–NLRX1 axis underlies the KRAS-inhibitor-induced mitophagy response and promotes drug resistance, providing a metabolic mechanism of KRAS inhibitor resistance. Thus, cytosolic AcCoA is a signalling metabolite that connects metabolism to mitophagy through its receptor NLRX1.


  • BAG2 releases SAMD4B upon sensing of arginine deficiency to promote tumor cell survival

    by Meng-Ying Chen, Chun-Yu Sun, Ru Zhao, Xiao-Lin Guan, Miao-Lin Li, Fan Zhang, Zhi-Han Wan, Jing-Xuan Feng, Miao Yin, Qun-Ying Lei, et al.


  • NUFIP1 integrates amino acid sensing and DNA damage response to maintain the intestinal homeostasis

    by Hui Ming, Jing Tan, Si-Yi Cao, Cheng-Ping Yu, Yu-Ting Qi, Chao Wang, Lei Zhang, Ying Liu, Jian Yuan, Miao Yin, et al.

    Nutrient availability strongly affects intestinal homeostasis. Here, we report that low-protein (LP) diets decrease amino acids levels, impair the DNA damage response (DDR), cause DNA damage and exacerbate inflammation in intestinal tissues of male mice with inflammatory bowel disease (IBD). Intriguingly, loss of nuclear fragile X mental retardation-interacting protein 1 (NUFIP1) contributes to the amino acid deficiency-induced impairment of the DDR in vivo and in vitro and induces necroptosis-related spontaneous enteritis. Mechanistically, phosphorylated NUFIP1 binds to replication protein A2 (RPA32) to recruit the ataxia telangiectasia and Rad3-related (ATR)–ATR-interacting protein (ATRIP) complex, triggering the DDR. Consistently, both reintroducing NUFIP1 but not its non-phospho-mutant and inhibition of necroptosis prevent bowel inflammation in male Nufip1 conditional knockout mice. Intestinal inflammation and DNA damage in male mice with IBD can be mitigated by NUFIP1 overexpression. Moreover, NUFIP1 protein levels in the intestine of patients with IBD were found to be significantly decreased. Conclusively, our study uncovers that LP diets contribute to intestinal inflammation by hijacking NUFIP1–DDR signalling and thereby activating necroptosis.


  • Open Access

    Correction To: Dietary folate drives methionine metabolism to promote cancer development by stabilizing MAT IIA

    by Jin-Tao Li, Hai Yang, Ming-Zhu Lei, Wei-Ping Zhu, Ying Su, Kai-Yue Li, Wen-Ying Zhu, Jian Wang, Lei Zhang, Jia Qu, et al.